- Home
- JELD vs EQ Comparison
JELD vs EQ Comparison
Compare JELD & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JELD | EQ |
|---|---|---|
| Founded | 1960 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.7M | 129.0M |
| IPO Year | 2016 | 2018 |
Fundamental Metrics
Financial Performance| Metric | JELD | EQ |
|---|---|---|
| Price | $1.73 | $2.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $3.43 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.4M | 878.7K |
| Earning Date | 05-04-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $0.29 |
| 52 Week High | $6.98 | $3.45 |
Technical Indicators
Market Signals| Indicator | JELD | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 54.53 |
| Support Level | $1.70 | $1.70 |
| Resistance Level | $2.15 | N/A |
| Average True Range (ATR) | 0.19 | 0.37 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 41.28 | 55.69 |
Price Performance
Historical ComparisonAbout JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.